Eurofins LifeCodexx – NIPT pioneer since 2010
At the forefront of this field in Europe
Since 2010 we have been developing clinically validated, non-invasive genetic tests. Two years later, we launched PrenaTest®, the first non-invasive prenatal test (NIPT) in Europe. At that time it could determine trisomy 21, which leads to the Down syndrome. Now the PrenaTest® is able examine the complete set of chromosomes for possible changes. Of course, we will also endeavor to remain at the forefront of this field well into the future.
| Nov 2019 | PrenaTest® now available for the detection of rare autosomal aneuploidy (rare autosomal aneuploidy, RAA). These are monosomies of chromosomes 13, 18 and 21 as well as monosomies and trisomies of chromosomes 1-12, 14-17, 19, 20 and 22. |
| Sept 2018 | Market launch of the NIPD-RhD – Non-invasive prenatal RhD genotyping from maternal blood |
| Aug 2017 | 5 years PrenaTest® – More than 80,000 successfully performed PrenaTest® analyzes in Germany with blood samples of pregnant women from 50 countries in Europe, the Middle East and Asia |
| April 2017 | Start of research and development of a molecular genetic assay for the early detection of pre-eclampsia (research alliance with the Charité Berlin) |
| Dez 2016 | CE approval for qPCR-based NIPT solution for the detection of fetal trisomy 21 (qNIPT) |
| Nov 2016 | Prospective clinical follow-up study with over 2,200 patients: Confirmation of the excellent test quality of the PrenaTest® |
| Mai 2015 | PrenaTest® now also for the determination of the 22q11.2 microdeletion |
| Dez 2014 | Start of development of a qPCR-based NIPT assay (qNIPT) with the aim of further reducing the test price and waiting time to the test result |
| Sept 2014 | Start of the development of an innovative NIPT data analysis system (PrenaBoxx®). |
| Jun 2014 | PrenaTest® now also determines sex chromosomal aneuploidy (Turner, Triple X, Klinefelter and XYY syndrome) |
| Feb 2014 | PrenaTest® now also applicable to twin pregnancies |
| Okt 2013 | Reduction of the waiting time to the test result to one week by introducing the PrenaTest®express |
| Juli 2013 | PrenaTest® now ready for use after the ninth week of pregnancy has been completed (week 9+0 since LMP) Introduction of the proprietary QuantYfeX® assay to measure the fetal fraction upon sample receipt |
| Feb 2013 | PrenaTest® now also determines fetal trisomies 13 and 18 |
| Aug 2012 | Market launch of the PrenaTest® – Europe’s first NIPT – for the determination of fetal trisomy 21 from gestational week 12+0 since LMP |
| Juni 2012 | CE Marking of proprietary bioinformatic analysis software (PrenaTest® DAP.plus) according to European IVD Directive |
| Sept 2011 | License agreement with Sequenom Inc. (USA) for the acquisition of rights of use of essential patents as a legal requirement for the conduct of non-invasive prenatal tests (NIPT) in Germany |
| April 2010 | Start of operative work on research and development of innovative and clinically validated non-invasive genetic tests |
